The sub-type distribution was as follows: 54.3% of patients had ER-positive/HER2-negative cancers, 32% of patients had HER2-positive cancers, and 13.3% of patients had triple negative breast cancers. Here, ERBB2 is linked to triple-negative breast carcinoma.